SKBI [SKYSTAR BIO-PHARMACEUTICAL] CERTNAS:
[]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-A12B: (Original Filing)
[Exh. No. Description 3.1 Charter of The Cyber Networkrporation filed with the State of Nevada (1 ) 3.2 Certificate of Amendment and Certificate of Change (2) 3.3 Certificate of Amendment torease Number of Authorized Shares ofmmon Stock (3) 3.4 Amended and Restated Bylaws ofystar Bio-Pharmaceuticalmpany (4)]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-A12B: Exh. No. Description 3.1 Charter of The Cyber
[Exh. No. Description 3.1 Charter of The Cyber Networkrporation filed with the State of Nevada (1 ) 3.2 Certificate of Amendment and Certificate of Change (2) 3.3 Certificate of Amendment torease Number of Authorized Shares ofmmon Stock (3) 3.4 Amended and Restated Bylaws ofystar Bio-Pharmaceuticalmpany (4)]
WX [WuXi PharmaTech (Cayman)] 20-F: (Original Filing)
[TABLE OF CONTENTS Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 28 ITEM 4A. UNRESOLVED STAFF COMMENTS 47 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 47 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND] [SECOND AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF WUXI PHARMATECH (CAYMAN) INC. Adopted by Special Resolution passed on July 27, 2007 and effective immediately upon completion of the Companys initial public offering of ordinary shares represented by American Depositary Shares Note: This document additionally reflects the amendment made to Article 80(1) on September 10, 2008 WuXi PharmaTech (Cayman) Inc. 1.] [EXECUTION VERSION ACT WUXI PHARMATECH (BVI) INC. CONVERTIBLE NOTE US$[Amount] 1 February [Date], 2007 Company Holder Principal Amount Maturity Date WUXI PHARMATECH (BVI) INC., a company incorporated and existing under the laws of the British Virgin Islands (the The following is a statement of the rights of the Holder of this Note and the conditions to which this Note] [SECOND AMENDMENT TO OFFICE AND INDUSTRIAL LEASE AGREEMENT LIBERTY PROPERTY PHILADELPHIA LIMITED PARTNERSHIP V Landlord WUXI APPTEC INC., Tenant APPTEC LABORATORY SERVICES, LLC, Assignor THIS AMENDMENT is entered into on December 30, 2008, by and between WHEREAS, WHEREAS NOW, THEREFORE, 1. All capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings given to them] [SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this Amendment) is made as of April 30, 2008 (the Amendment Date) by and between ALPHA EXCHANGE, LLC, a Georgia limited liability company (successor-in-interest to Highwoods Realty Limited Partnership) (Landlord) and WUXI APPTEC, INC., a Delaware corporation (f/k/a Apptec Laboratory Services, Inc., a Delaware corporation) (Tenant). RECITALS Landlord and Tenant hereby] [FIRST AMENDMENT TO LEASE Amendment , Landlord Tenant This First Amendment to Lease (this Recitals: A. Original Lease Original Premises B. Expansion Premises Expansion Date C. D. NOW, THEREFORE, Landlord and Tenant agree as follows: 1. Interpretation Lease 2. Expansion of Premises 1 First Amendment to Lease AppTec Laboratory Services, Inc. 3. Extension of Initial Term 4. Net Rent Period] [LIST OF SUBSIDIARIES WX (BVI) Limited, incorporated in the British Virgin Islands. WuXi AppTec (BVI) Inc., incorporated in the British Virgin Islands. Kaipara Enterprises Limited, incorporated in Cyprus. Klivia Investments Sp. zo.o., incorporated in Poland. Klivia Investments Sp. zo.o. Luxembourg Branch, incorporated in Luxembourg. WuXi AppTec Co., Ltd., incorporated in the Peoples] [Certification by the Chief Executive Officer I, Ge Li, Chief Executive Officer of WuXi PharmaTech (Cayman) Inc. (the Company), certify that: 1. I have reviewed this annual report on Form 20-F of the Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [Certification by the Acting Chief Financial Officer I, Edward Hu, Acting Chief Financial Officer of WuXi PharmaTech (Cayman) Inc. (the Company), certify that: 1. I have reviewed this annual report on Form 20-F of the Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact] [Section 906 of the Sarbanes-Oxley Act of 2002 Ge Li Chief Executive Officer] [Section 906 of the Sarbanes-Oxley Act of 2002 Edward Hu Acting Chief Financial Officer] [Commerce & Finance Law Offices 6F NCI Tower, A12 Jianguomenwai Avenue, Chaoyang District, Beijing, PRC; Postcode: 100022 Tel:(8610) 65693399 Fax: (8610) 65693838,65693836, 65693837, 65693839 www.tongshang.com.cn E-mail Add: beijing@tongshang.com Website: June 25, 2009 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131 Peoples Republic of China RE: WUXI PHARMATECH (CAYMAN) INC. Dear Sirs/Madams, Company We have] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-146730 on Form S-8 of our reports dated June 25, 2009, relating to the financial statements and financial statement schedule of WuXi PharmaTech (Cayman) Inc., and the effectiveness of WuXi PharmaTech (Cayman) Inc.s internal control over financial reporting, appearing in this Annual]
WX [WuXi PharmaTech (Cayman)] 20-F: TABLE OF CONTENTS Page INTRODUCTION 1 2 PART
[TABLE OF CONTENTS Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 28 ITEM 4A. UNRESOLVED STAFF COMMENTS 47 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 47 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND] [SECOND AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF WUXI PHARMATECH (CAYMAN) INC. Adopted by Special Resolution passed on July 27, 2007 and effective immediately upon completion of the Companys initial public offering of ordinary shares represented by American Depositary Shares Note: This document additionally reflects the amendment made to Article 80(1) on September 10, 2008 WuXi PharmaTech (Cayman) Inc. 1.] [EXECUTION VERSION ACT WUXI PHARMATECH (BVI) INC. CONVERTIBLE NOTE US$[Amount] 1 February [Date], 2007 Company Holder Principal Amount Maturity Date WUXI PHARMATECH (BVI) INC., a company incorporated and existing under the laws of the British Virgin Islands (the The following is a statement of the rights of the Holder of this Note and the conditions to which this Note] [SECOND AMENDMENT TO OFFICE AND INDUSTRIAL LEASE AGREEMENT LIBERTY PROPERTY PHILADELPHIA LIMITED PARTNERSHIP V Landlord WUXI APPTEC INC., Tenant APPTEC LABORATORY SERVICES, LLC, Assignor THIS AMENDMENT is entered into on December 30, 2008, by and between WHEREAS, WHEREAS NOW, THEREFORE, 1. All capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings given to them] [SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this Amendment) is made as of April 30, 2008 (the Amendment Date) by and between ALPHA EXCHANGE, LLC, a Georgia limited liability company (successor-in-interest to Highwoods Realty Limited Partnership) (Landlord) and WUXI APPTEC, INC., a Delaware corporation (f/k/a Apptec Laboratory Services, Inc., a Delaware corporation) (Tenant). RECITALS Landlord and Tenant hereby] [FIRST AMENDMENT TO LEASE Amendment , Landlord Tenant This First Amendment to Lease (this Recitals: A. Original Lease Original Premises B. Expansion Premises Expansion Date C. D. NOW, THEREFORE, Landlord and Tenant agree as follows: 1. Interpretation Lease 2. Expansion of Premises 1 First Amendment to Lease AppTec Laboratory Services, Inc. 3. Extension of Initial Term 4. Net Rent Period] [LIST OF SUBSIDIARIES WX (BVI) Limited, incorporated in the British Virgin Islands. WuXi AppTec (BVI) Inc., incorporated in the British Virgin Islands. Kaipara Enterprises Limited, incorporated in Cyprus. Klivia Investments Sp. zo.o., incorporated in Poland. Klivia Investments Sp. zo.o. Luxembourg Branch, incorporated in Luxembourg. WuXi AppTec Co., Ltd., incorporated in the Peoples] [Certification by the Chief Executive Officer I, Ge Li, Chief Executive Officer of WuXi PharmaTech (Cayman) Inc. (the Company), certify that: 1. I have reviewed this annual report on Form 20-F of the Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [Certification by the Acting Chief Financial Officer I, Edward Hu, Acting Chief Financial Officer of WuXi PharmaTech (Cayman) Inc. (the Company), certify that: 1. I have reviewed this annual report on Form 20-F of the Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact] [Section 906 of the Sarbanes-Oxley Act of 2002 Ge Li Chief Executive Officer] [Section 906 of the Sarbanes-Oxley Act of 2002 Edward Hu Acting Chief Financial Officer] [Commerce & Finance Law Offices 6F NCI Tower, A12 Jianguomenwai Avenue, Chaoyang District, Beijing, PRC; Postcode: 100022 Tel:(8610) 65693399 Fax: (8610) 65693838,65693836, 65693837, 65693839 www.tongshang.com.cn E-mail Add: beijing@tongshang.com Website: June 25, 2009 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131 Peoples Republic of China RE: WUXI PHARMATECH (CAYMAN) INC. Dear Sirs/Madams, Company We have] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-146730 on Form S-8 of our reports dated June 25, 2009, relating to the financial statements and financial statement schedule of WuXi PharmaTech (Cayman) Inc., and the effectiveness of WuXi PharmaTech (Cayman) Inc.s internal control over financial reporting, appearing in this Annual]
CPHI [CHINA PHARMAS,] CORRESP: (Original Filing)
[June 24, 2009 Attn: Mr. Jim B. Rosenberg Re: China Pharma Holdings, Inc. Form 10-K for the Fiscal Year Ended December 31, 2008 Filed March 17, 2009 Form 10-KSB/A for the Fiscal Year Ended December 31, 2007 Forms 10-Q/A for the Quarterly Periods Ended March 31 and June 30, and September 30, 2008 Filed March 12, 2009 File No. 000-29523]
CPHI [CHINA PHARMAS,] CORRESP: June 24, 2009 Attn: Mr. Jim B. Rosenberg
[June 24, 2009 Attn: Mr. Jim B. Rosenberg Re: China Pharma Holdings, Inc. Form 10-K for the Fiscal Year Ended December 31, 2008 Filed March 17, 2009 Form 10-KSB/A for the Fiscal Year Ended December 31, 2007 Forms 10-Q/A for the Quarterly Periods Ended March 31 and June 30, and September 30, 2008 Filed March 12, 2009 File No. 000-29523]
CPHI [CHINA PHARMAS,] 10-Q/A: (Original Filing)
[EXPLANATORY NOTE Except as set forth below, this Form 10-Q/A does not modify, amend or update in any way any other items or disclosure in the Form 10-Q. This Form 10-Q/A continues to speak as of the date of the original Form 10-Q and other than as specifically reflected in the Form 10-Q/A does not reflect events occurring after the] [Certification of Chief Executive Officer I, Zhilin Li, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by] [Financial Certification of Chief Officer I, Frank Waung, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, Zhilin Li Chief Executive Officer EX-32.1 4 cph10qaex321033109.htm] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, Frank Waung Chief Financial Officer EX-32.2 5 cph10qaex322033109.htm]
CPHI [CHINA PHARMAS,] 10-Q/A: EXPLANATORY NOTE Except as set forth below, this
[EXPLANATORY NOTE Except as set forth below, this Form 10-Q/A does not modify, amend or update in any way any other items or disclosure in the Form 10-Q. This Form 10-Q/A continues to speak as of the date of the original Form 10-Q and other than as specifically reflected in the Form 10-Q/A does not reflect events occurring after the] [Certification of Chief Executive Officer I, Zhilin Li, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by] [Financial Certification of Chief Officer I, Frank Waung, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, Zhilin Li Chief Executive Officer EX-32.1 4 cph10qaex321033109.htm] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, Frank Waung Chief Financial Officer EX-32.2 5 cph10qaex322033109.htm]
CPHI [CHINA PHARMAS,] 10-K/A: (Original Filing)
[o x o x x o x Large accelerated filer o Accelerated filer o Non-accelerated filer o] [January 11, 2008 1) A retainer of RMB 40,000 per year, payable quarterly within 5 days of the start of the quarter. If you agree to the terms and conditions stated above, please sign and date this letter below. Chairman of the Board EX-10.7 2 cph10kaex107123108.htm] [January 11, 2008 1) A retainer of RMB 40,000 per year, payable quarterly within 5 days of the start of the quarter. If you agree to the terms and conditions stated above, please sign and date this letter below. Chairman of the Board EX-10.8 3 cph10kaex108123108.htm] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION OF CHIEF FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Frank Waung, certify that: 2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Zhilin Li Chief Executive Officer EX-32.1 6 cph10kaex321123108.htm] [CERTIFICATION OF CHIEF FINANCIAL OFFICER 18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Frank Waung Chief Financial Officer EX-32.2 7 cph10kaex322123108.htm]
